Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers
2026 · Journal of Medicinal Chemistry · 0 citations
https://doi.org/10.1021/acs.jmedchem.5c02445